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°shared last 
Structured Abstract 
Aims 
Mental health symptoms are frequent in women with gestational diabetes mellitus (GDM) 
and may influence glycemic control. We therefore investigated if mental health symptoms 
(high depression and low well-being scores) predicted a need for glucose-lowering 
medication and if this use of medication influenced the trajectory of mental health during 
pregnancy and in the postpartum period.  
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Methods 
We included 341 pregnant women from a cohort of GDM women in a Swiss University 
Hospital. The World Health Organization Well-being Index was collected at the first and last 
GDM and at the postpartum clinical visits and the Edinburgh Postnatal Depression Scale at 
the first GDM and the postpartum clinical visits. Medication intake was extracted from 
participants’ medical records. We conducted linear and logistic regressions with depression 
as an interaction factor. 
Results 
Mental health symptoms did not predict a need for medication (all p≥0.29). Mental health 
improved over time (both p≤0.001) and use of medication did not predict this change (all 
p≥0.40). In women with depression symptoms, medication was associated with less 
improvement in well-being at the postpartum visit (p for interaction=0.013).  
Conclusions 
Mental health and glucose-lowering medication did not influence each other in an 
unfavourable way in this cohort of GDM women.  
Key Words: Depression, insulin, metformin, postpartum, pregnancy, well-being 
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1. Introduction 
Gestational diabetes mellitus (GDM) is defined as a glucose intolerance diagnosed in the 
second or third trimester of pregnancy that does not fulfil the criteria of overt diabetes (Cefalu et al. 
2019). Lifestyle interventions focusing on diet and physical activity are usually recommended as the 
primary therapeutic strategy (Blumer et al. 2013; Gilbert et al. 2019; Cefalu et al. 2019; American 
Diabetes Association 2020) for glucose control during pregnancy. When lifestyle interventions fail to 
achieve glycemic targets (Lehmann, Troendle, and Brändle 2009; Blumer et al. 2013; Metzger et al. 
2007; American Diabetes Association 2020), glucose-lowering medication is initiated. In accordance 
with the American Diabetes Association (ADA) guidelines, insulin is prescribed more frequently in 
Switzerland, as it does not cross the placenta (Cefalu et al. 2019; American Diabetes Association 
2020), although metformin can also be prescribed (Webber, Charlton, and Johns 2015). According to 
a recent study and similarly to our practice, insulin is the most frequently used glucose-lowering 
medical therapy during GDM pregnancy across countries (Cesta et al. 2019). 
Women with GDM are more likely to suffer from mental health symptoms. Indeed, women 
with GDM have higher rates of depression during pregnancy and in the postpartum period, 
compared to women without GDM (Bennett et al. 2004; Damé et al. 2017; Daniells et al. 2003; 
Wilson et al. 2019; Alexandre et al. 2017). Mental health symptoms therefore represent an 
important factor to consider in women with GDM, as it may interfere with their capacity to adhere 
to lifestyle interventions (Molyneaux et al. 2018). Indeed, symptoms of depression may reduce an 
individual’s coping abilities and may lead to disordered eating behaviors and lower dietary quality 
(Fowles, Murphey, and Ruiz 2011). Depression may also lead individuals to eat as a strategy to 
relieve themselves of negative symptoms (Christenson et al. 2016) and may decrease women’s 
motivation to conduct physical activity (Carter and Swardfager 2016). Thus, mental health symptoms 
may impact both diet and physical activity and lead to higher glycaemia during pregnancy (Blumer et 
al. 2013; Ruchat and Mottola 2013). Secondly, mental health symptoms may be directly related to 
worsened metabolic control in women with GDM. Overall, depression is associated with a higher risk 
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of future GDM (Hinkle et al. 2016). Similarly, higher anxiety and depression scores, as well as stress 
perception, are associated with higher glycaemia during pregnancy (Horsch et al. 2016; Hinkle et al. 
2016). However, even if mental health symptoms can have a direct impact on glycaemia and 
adherence to lifestyle interventions, it is not clear if it increases the need for glucose-lowering 
medication in women with GDM. In addition, we are not aware of any study investigating whether 
the presence of clinically relevant depression symptoms might augment the need for glucose-
lowering medication. This could have an important impact on the identification and care of these 
women.  
 Conversely, there might also be an association between the need for glucose-lowering 
medication and subsequent mental health symptoms. Indeed, our clinical experience shows that 
many women are willing to adjust their lifestyle in order to avoid medication and particularly the 
burden of insulin injections. In addition, the need for glucose-lowering medication could lead to a 
feeling of failure. To our knowledge, only one study showed that insulin use was not a predictor for 
postpartum depression in women with GDM (Nicklas et al. 2013). Thus, the potential impact of 
glucose-lowering medication on the mental health of women with GDM and in the postpartum 
period remains understudied. It is important to study this question, as mental health symptoms have 
been shown to be higher in the postpartum period in women with GDM (Wilson et al. 2019) and 
may have important adverse effects on the health of the mother (Christenson et al. 2016; Herring et 
al. 2008) and the infant (Grace, Evindar, and Stewart 2003; Cooper and Murray 1998; Cato et al. 
2019). To study these questions, we chose both depressive symptoms (Hinkle et al. 2016; Blumer et 
al. 2013; Ruchat and Mottola 2013) and well-being (Robertson et al. 2012; Hochberg et al. 2012) as 
markers of mental health, as they had either shown their impact on glycemic control or were studied 
in patients with diabetes. 
This study was therefore conducted to 1) investigate if mental health symptoms, described 
here as high depressive symptoms and low well-being scores, in women with GDM predict a need 
for glucose-lowering medication during pregnancy and 2) describe the overall trajectory of mental 
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health in these women and investigate if the need for glucose-lowering medication independently 
predicts mental health symptoms during and after pregnancy. We also studied if clinically relevant 
depression symptoms would influence these associations, i.e., if they are different in the presence of 
depressive symptoms. 
2. Materials and Methods 
2.1 Setting and patient population 
This prospective clinical cohort study included pregnant women diagnosed with GDM 
according to the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) and 
ADA guidelines (Metzger et al. 2010; Blumer et al. 2013; American Diabetes 2019). These women 
were taken care of in the Diabetes and Pregnancy Unit at the Lausanne University Hospital 
(Switzerland) between 2016 and 2019 and gave written consent. The Human Research Ethics 
Committee of the Canton de Vaud approved the study protocol (326/15). 
 
2.2 Inclusion and exclusion criteria 
This study is part of an ongoing prospective clinical cohort of women with GDM, for which 
participating women provided signed consent.  Out of the 959 participating women, we selected 
those who corresponded to our eligibility criteria (n=875) (please see Figure 1), who presented after 
January 2016 (when we started systematically distributing mental health questionnaires) (n=800), 
and were present during predefined time points that are essential (first and last GDM visit) in order 
to have baseline mental health assessed and valid information regarding glucose-lowering 
medication (the two main aims of the study). Thus, 341 women with GDM were included in the 
current analysis. 
 
2.3 GDM management/clinical care 
At the first clinical visit after the confirmation of GDM diagnosis, women receive information 
on GDM from a nurse or medical doctor specialized in GDM and are taught to perform capillary 
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blood glucose (CBG) measures. Women are then asked to monitor their CBG 4 times per day (fasting 
blood glucose (FBG) in the morning and 2-hour (or 1-hour) postprandial blood glucose after each 
meal) (Arditi C 2017; American Diabetes Association 2020). A week later, women are seen by a 
dietician and receive recommendations regarding their CBG, eating habits and weight gain (Blumer 
et al. 2013) and are encouraged to increase their physical activity (Colberg, Castorino, and Jovanovič 
2013). If despite lifestyle changes (diet and physical activity) glucose values remain above targets 
two or more times during a 1-2-week period, glucose-lowering medication is introduced (Lehmann, 
Troendle, and Brändle 2009; Metzger et al. 2007). Glucose-lowering medication type depends on 
glucose values (i.e., insulin in case of relatively high values), patient characteristics (i.e., Body Mass 
Index; BMI) and patient preference, but in the vast majority of cases insulin is the preferred 
treatment over metformin. Short-acting insulin analogues are introduced and adapted to achieve a 
2-hour postprandial glucose value ≤7 mmol/l (alternatively 1-hour postprandial glucose ≤8 mmol/l), 
and long-acting insulin analogues to achieve FBG ≤5.3 mmol/l (Carroll and Kelley 2014; American 
Diabetes 2019; American Diabetes Association 2020). Women are then followed until delivery and 
an oral glucose tolerance test (oGTT) is performed between 6-8 weeks postpartum (American 
Diabetes Association 2020). 
 
2.4 Measures 
2.4.1 Maternal depression symptoms 
Edinburgh Postnatal Depression Scale (EPDS): The EPDS was used in the current study to 
measure depressive symptoms. The questionnaire has been validated in pregnant women 
(Bunevicius et al. 2009), as well as in a French population, and good psychometric properties have 
been reported (Guedeney and Fermanian 1998). Symptoms of depression in the preceding 7 days 
were assessed (Cox, Holden, and Sagovsky 1987) at the women’s first GDM clinical visit and at the 6-
8 weeks postpartum clinical visit. We distributed this self-report questionnaire in French and in 
English. For women who did not understand these languages, we ensured that a certified 
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professional translator helped them complete it. Each item of this questionnaire is scored on a 4-
point scale, the minimum and maximum total scores being 0 and 30, respectively. For our interaction 
analysis, we additionally created a dichotomous variable using a cut-off of ≥ 11 to separate women 
with or without clinically relevant depression scores (Bunevicius et al., 2009). For this cut-off, the 
terminology “clinically relevant depression symptoms” was chosen, given that clinical interviewing 
represents the gold standard to diagnose depression (Watson, Zimmerman, Cohen, & Dominik, 
2009).  
2.4.2 Maternal well-being index 
WHO-Five Well-Being Index (WHO-5): The WHO-5 was used to measure well-being in our 
sample, as this questionnaire has shown adequate validity as an outcome measure in clinical studies 
(Henkel et al. 2003; Topp et al. 2015). It has been used extensively in endocrinology, and the French 
version has shown good psychometric properties (Topp et al. 2015; Hochberg et al. 2012). This 5-
item self-report questionnaire assessed the subjective well-being of the participants (Topp et al. 
2015) at the first and last GDM clinical visit and at the 6-8 weeks postpartum clinical visit. In 
accordance with the ethnical diversity of our patients, we used validated versions of the 
questionnaire in several languages. The items are measured on a 5-point Likert scale ranging from 0 
‘at no time’ to 5 ‘all of the time’. The final score is then calculated by multiplying the total score by 4; 
thus, the final score ranges from 0 to 100.  
2.4.3 Glucose-lowering medication 
Information regarding glucose-lowering medication intake was retrieved from the medical 
records at the last GDM clinical visit. With this information, two types of variables were generated. 
First, a dichotomous (yes, no) variable named “glucose-lowering medication” was created to know if 
women did or did not take glucose-lowering medication during their pregnancy. For additional and 
more detailed analysis, a second variable was comprised of four categories: no glucose-lowering 
medication intake (1), metformin only (2), long-acting (basal) bedtime insulin (±metformin) (3), and 
short-acting (meal) insulin (± long-acting bedtime insulin and/or metformin) (4). These categories of 
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glucose-lowering medication were formed based on degrees of burden to the participants: the 
injections with short-acting insulins were considered being most burdensome (as women have to 
carry syringes with them wherever they go and inject before the meals, often outside of their home), 
and no glucose-lowering medication, was considered as putting a lower strain on women and 
metformin was in between. Indeed, previous research has shown that metformin is better accepted 
in women with GDM and that insulin is more burdensome (Rowan et al. 2008). This variable is 
named “detailed glucose-lowering medication” and the reference category was 1=no glucose-
lowering medication intake. 
2.4.4 Sociodemographic, medical and anthropometric variables  
At the first GDM clinical visit, maternal age, weeks of gestation, educational level, social 
support, prior GDM diagnosis, and family history of diabetes information were collected during the 
clinical consultation or extracted from medical records. Furthermore, glycated haemoglobin (HbA1c) 
was measured using a chemical photometric method (conjugation with boronate; Afinion®) (Panel 
2016; Wood et al. 2012) and Body Mass Index (BMI) at first GDM clinical visit was calculated based 
on measured height and weight using the formula weight (kg)/[height(m)]2.  
2.5 Data analysis 
All analyses were carried out with SPSS (IBM Corp. Released 2017. IBM SPSS Statistics for 
Windows, Version 25.0. Armonk, NY: IBM Corp.). Descriptive statistics were conducted for socio-
demographic variables (Table 1). Continuous and normally distributed variables were described as 
means and standard deviations and ordinal outcomes were described as frequencies and 
percentages. Statistical significance was set at p<0.05. 
Regarding the first objective, investigating the prospective association between mental 
health symptoms and the subsequent need for glucose-lowering medication, we conducted logistic 
regression analyses with the dichotomous glucose-lowering medication variable as the dependent 
variable. To see if this relationship was different in women with higher depression scores, we added 
the “clinically relevant depression symptoms” interaction term (dichotomous variable created from 
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the EPDS scale) for the association between well-being and the glucose-lowering medication 
dichotomous variable. This was possible, as the correlation between the predictor (well-being 
scores) and the interaction term (clinically relevant depression symptoms) was only small to 
moderate (correlation coefficient r=-0.47). This interaction term could not be added when 
depression scores were the predictor, as the correlation was too high between this predictor and the 
interaction term (clinically relevant depression symptoms; correlation coefficient r=0.81) and both of 
these measures; depression scores and clinically relevant depression symptoms are derived from the 
same questionnaire. Given that none of the interactions were significant in our first aim, we did not 
conduct further stratification analyses. 
Regarding the second objective, we first evaluated the trajectory of depression and well-
being scores over time during and after pregnancy in women with GDM using a linear mixed effects 
model. Indeed, it seemed important to first gain knowledge about the general trajectory of mental 
health in women with GDM in pregnancy and in the postpartum period. Then, we assessed the 
prospective association between the use of glucose-lowering medication and subsequent mental 
health at the end of pregnancy (well-being scores) and in the postpartum period (well-being and 
depression scores). We performed linear regressions with occurrence of glucose-lowering 
medication as binary predictor (yes, no), and also with the detailed glucose-lowering medication as 
categorical predictor. Finally, to see if the impact of glucose-lowering medication (yes, no) on mental 
health was different if clinically relevant depression symptoms were present, we added the 
“clinically relevant depression symptoms” interaction term. If any of the interactions were 
significant, we conducted further stratification analyses, separating women with clinically relevant 
depression symptoms from those without. This was only the case for the association between the 
dichotomous glucose-lowering medication variable during pregnancy and well-being at the 
postpartum clinical visit. 
For all regressions, we used two models (model 1 & 2). In model 1, we adjusted for maternal 
age and gestational weeks at the first GDM clinical visit (Crowther et al. 2005; Ruohomäki et al. 
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2018). In model 2, we added variables that were significantly correlated with the respective 
dependent variable. We tested the following potential confounder variables: family history of 
diabetes, prior GDM diagnosis, BMI and HbA1c at the first GDM clinical visit, social support, and 
educational level. For the first objective, family history of diabetes, social support, educational level, 
and HbA1c were added as confounders in model 2. For the second objective, only family history of 
diabetes was added as a confounder in model 2 when the dependent variable was well-being, while 
there was no model 2 when the dependent variable was depression, as none of the additional 
confounders correlated with this score. In an additional step, we also adjusted for baseline mental 
health variables at the first GDM clinical visit in order to investigate if the associations changed. 
Given that this did not change the results (data not shown), we used the simpler model (model 2). In 
analogy, we also tested completely unadjusted models. However, as is common practice, we 
adjusted for age and gestational age in our basic model 1.  
 
3. Results 
 
Table 1 shows detailed descriptive information regarding sociodemographic and medical 
parameters. Women had a mean age of 33.62±5.34 years and a mean gestational age of 28.85±3.38 
weeks at first GDM clinical visit and a mean gestational age of 36.44±1.28 at the last GDM clinical 
visit. 25.2% of women suffered from clinically relevant depression symptoms and 47.8% of women 
took glucose-lowering medication during their GDM pregnancy. In our sample, 120 (35.2%) women 
were pregnant for the first time and 167 (49%) had no previous babies. Out of 174 (51%) women 
who were multiparas, 9.2% (n=16) had had previous GDM.  
3.1 Prospective associations between mental health and subsequent need for glucose-
lowering medication during pregnancy 
Women’s mental health at the first GDM clinical visit did not predict a subsequent need for 
glucose lowering medication during pregnancy, neither for depression (OR=1.0 (CI=0.96 – 1.04; 
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p=0.94) nor for well-being scores (OR=0.99 (CI=0.98 – 1.01; p=0.29). These results remained similar 
in model 2 (OR=0.99 (CI=0.93 – 1.04; p=0.62) and (OR=0.99 (CI=0.98 – 1.01; p=0.30)).  
The association between the well-being score and subsequent need for glucose-lowering 
medication was not significantly different between women with or without clinically relevant 
depression symptoms at the first GDM clinical visit (p for interaction = 0.80). 
3.2 Prospective associations between the need for glucose-lowering medication and 
subsequent mental health during and after pregnancy  
Mental health improved significantly over time in the whole sample (see Figure 2a & 2b). 
Thus, depression scores decreased by 26% between the first GDM clinical visit and the postpartum 
clinical visit (B=-1.74, CI= -2.22 – -1.26, p<0.01). Specifically, mean scores changed from a 7.43 ± 5.46 
at the first GDM clinical visit to 5.90 ± 4.40 at the postpartum clinical visit. Well-being scores 
increased overall by 7% between the first GDM clinical visit and the postpartum clinical visit (B=2.49, 
CI= 1.34 – 3.64, p<0.01). More specifically, the mean well-being scores changed from 60.55 ± 20.368 
at the first GDM clinical visit to 67.59 ± 17.96 at the end of pregnancy, and to 65.43 ± 18.79 at the 
postpartum clinical visit.  
The need for glucose-lowering medication during pregnancy had no impact on subsequent 
mental health during and after pregnancy. This was the case for the depression scores at the 
postpartum clinical visit (B=0.29 (CI=-0.76 – 1.34; p=0.59)), well-being scores at the end of pregnancy 
(B=2.01 (CI=-6.72 – 2.69; p=0.40) in model 1, B=2.26 (CI=-6.84 – 2.32; p=0.33) in model 2) and well-
being scores at the postpartum clinical visit (B=-0.15 (CI=-4.59 – 4.30; p=0.95) in model 1, B=0.25 
(CI=-4.18 – 4.69; p=0.91) in model 2). These results remained unchanged when controlled for 
baseline mental health at the first GDM clinical visit (data not shown). 
When looking at the detailed glucose-lowering medication, we found very similar results 
(see Table 2), with the exception of metformin, used in 13 women, that was associated with 
improved well-being in the postpartum period compared to no glucose-lowering medication 
(p=0.03, see Table 2).  
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Regarding the interaction effect of clinically relevant depression symptoms on the 
association between glucose-lowering medication and mental health, we found no interaction effect 
on the depression score at the postpartum clinical visit (p=0.93), nor on the well-being score at the 
end of pregnancy (p=0.49). However, in women with clinically relevant depression symptoms, 
glucose-lowering medication in pregnancy was associated with a lower improvement in the well-
being score at the postpartum clinical visit compared to women without clinically relevant 
depression symptoms (p for interaction = 0.01, Figure 2b). Further stratification analysis revealed 
that, in women with clinically relevant depression symptoms, glucose-lowering medication lead to a 
non-significant decrease in well-being of -8.82 points (p=0.063), whereas in women without 
depression symptoms, glucose-lowering medication lead to a non-significant increase of 4.02 points 
(p=0.12). 
4. Discussion 
This study investigated a clinical cohort of women with GDM and demonstrated that mental 
health symptoms at the first GDM clinical visit did not predict a later need for glucose-lowering 
medication. Furthermore, mental health improved throughout pregnancy and in the early 
postpartum period. Importantly, the need for glucose-lowering medication was not associated with 
future mental health symptoms during and after pregnancy. Clinically relevant depression symptoms 
at first GDM clinical visit did not interact with these investigated associations, except for well-being 
scores at the postpartum clinical visit, which improved less in women with clinically relevant 
depression symptoms.  
To the best of our knowledge, this is the first study to report that there is no association 
between mental health symptoms and later need for glucose-lowering medication in women with 
GDM. Previous research shows that mental health symptoms are associated with both a lower 
adherence to lifestyle interventions and thus can lead to higher glycaemia (Molyneaux et al. 2018; 
Carter and Swardfager 2016; Ruchat and Mottola 2013), and, a higher glycaemia in pregnancy 
(Hinkle et al. 2016; Horsch et al. 2016). Both, low adherence to lifestyle interventions and higher 
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glycaemia would be expected to lead to a more frequent need for glucose-lowering medication. 
Surprisingly, this was not the case in our population, nor was this influenced by the presence of 
clinically relevant depression symptoms. These symptoms were present in 25.2% of our cohort and 
the mean score was 7.43 at the first GDM clinical visit, which is comparable to other studies in 
women with GDM and, for some, in normal pregnancies (Damé et al. 2017; Varela et al. 2017; Mak 
et al. 2019; Wilson et al. 2019). In our sample, the depression symptoms declined by 26% to a mean 
score of 5.9 at the postpartum clinical visit. This score is similar to a previous sample of GDM women 
in the postpartum period (Nicklas et al. 2013). In the current sample, well-being scores also 
augmented by 7% between first GDM clinical visit and the postpartum clinical visit, and attained 
similar scores as previously reported in healthy pregnancies and the postpartum period (Mortazavi 
et al. 2015), the scores at the last GDM clinical visit cannot be compared to previous research as we 
are not aware of such studies. The fact that well-being at the first GDM clinical visit and the 
postpartum clinical visit in our sample is not lower than that of normal pregnancies is reassuring, 
given that women with GDM usually have higher depression scores than the general population 
(Bennett et al. 2004; Damé et al. 2017), and that depression is known to be negatively associated 
with well-being in pregnancy (Wersebe et al. 2018). We believe that the improvements found in 
mental health over time could be due to the social support the patients receive from clinicians 
(Barger, Messerli-Bürgy, and Barth 2014). Indeed, women are seen a for a few clinical appointments 
during their pregnancy and receive tailored advice and attention from our team of specialized 
clinicians, which could also have improved well-being and lowered depression in our population, 
despite the need for frequent glucose monitoring and lifestyle adjustments. 
The improvements found in mental health were not influenced by glucose-lowering 
medication intake, as glucose-lowering medication did not predict future well-being or depression 
scores during or after pregnancy. This result is comparable to one previous study in women with 
GDM showing that use of insulin during pregnancy was not associated to depressive symptoms in 
the postpartum period (Nicklas et al. 2013), while overall well-being or mental health during 
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pregnancy has not been previously investigated. These findings may reassure clinicians when they 
need to initiate glucose-lowering medication with patients, as mental health does not seem to be 
affected by medication intake, at least in our population. This could possibly mean that women do 
not view glucose-lowering medication as a failure of their lifestyle behavior change, but rather as 
another acceptable solution to lower their glucose. Also, glucose-lowering medication may bring 
them some relief if lifestyle adaptations alone did not yield the desired effect (Rowan et al. 2008). 
Another novel, though, secondary finding was that the use of metformin was associated with 
improved well-being in the postpartum period. Although, this result is in line with previous research 
showing that metformin is the preferred type of medication in women with GDM (Rowan et al. 
2008), this result should be interpreted with caution and needs to be replicated in future research, 
as this concerned only a very small number of women (n=13).  
The presence of clinically relevant symptoms of depression did not interact with our findings 
except that in women with relevant depression symptoms, glucose-lowering medication during 
pregnancy was related to lower well-being scores in the postpartum period compared to those with 
no glucose-lowering medication. In these women, the combination of glucose-lowering medication, 
higher depression scores and having to care for a newborn might cumulate and contribute to the 
lower increase and lower absolute wellbeing scores. Hajos et al. showed that a score of 50 on the 
WHO-5 Well-Being Index, which is close to our mean score of 54 can be interpreted as suboptimal 
well-being and warrants further testing for depression  (Hajos et al. 2013). This is especially 
important, as depression in the postpartum period can have adverse impacts on the mother’s 
cardio-metabolic health (Christenson et al. 2016; Herring et al. 2008; Carter and Swardfager 2016). 
Depression in the postpartum may also lead to negative consequences for the infant, such as lower 
duration of breastfeeding (Cato et al. 2019) and to relationship difficulties between the mother and 
her infant, which have shown to be prospectively associated with suboptimal development of 
cognitive (for example language development) and emotional functioning of the infant (Grace, 
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Evindar, and Stewart 2003; Cooper and Murray 1998). Thus, these women should be identified and 
may need psychological interventions.  
4.1 Strengths and limitations 
This study has several strengths. First, we included a “real-life” multiethnic diverse 
population and patients completed the questionnaires either in their native language or with the 
help of a certified professional translator. Second, we included influential confounding variables; in 
our basic model we controlled for variables of interest in the GDM population (Crowther et al. 2005; 
Ruohomäki et al. 2018), and in our second model, we added confounding variables that correlated 
significantly to our dependent variables. Finally, we also made sure that well-being and depression 
scores at first GDM clinical visit did not alter the results by controlling for these results with a third 
model (data not shown). 
Limitations of the study include the lack of information about the women’s physical activity 
and diet behaviors, which could have been important confounders for the intake of glucose-lowering 
medication. Furthermore, we do not have information about mental health variables before the first 
GDM clinical visit or mental health measurements other than depression or well-being scores after 
their GDM diagnosis (such as anxiety symptoms), which could be seen as a limitation. The data about 
metformin needs to be interpreted with caution, as they concern only 13 (3.8%) of women and the 
choice to treat with metformin might be biased. As no exclusion criteria were applied for the timings 
of the clinical visits, this could have had an influence on the women’s mental health variables. 
Women came for their first GDM clinical visit at a mean of 28.85 (3.38) weeks of gestational age. 
Allover, 8 (2.4%) women came before 20 or 24 weeks of gestation as no women came between 20 
and 24 weeks of gestation and 29 (8.7%) came later than 32 weeks of gestation for their first GDM 
clinical visit. The last GDM clinical visit took place at a mean of 36.44 (1.28) weeks; all of the women 
came between 32 and 40 weeks of gestation and of those, 55 (23.7%) came before 36 weeks of 
gestation. We therefore performed the main analyses in a limited sample of 157 women who came 
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between 24-32 weeks of gestation to the first GDM clinical visit and who were at 36 weeks of 
gestation or more at the last GDM clinical visit and results did not significantly change. 
5. Conclusion 
This prospective clinical cohort study found that mental health symptoms do not lead to a 
higher need for glucose-lowering medication in women with GDM. This finding is reassuring, as it 
means that even if mental health symptoms can impact both on lifestyle behavior and on glycaemia, 
it does not necessarily implicate a higher need for glucose-lowering medication. Secondly, glucose-
lowering medication did not worsen the trajectory of mental health symptoms in this GDM 
population. This is reassuring for clinicians, as it demonstrates that glucose-lowering medication can 
be prescribed without the risk of worsening mental health symptoms (symptoms of depression and 
lower well-being in particular). Even if mental health symptoms did not affect the need for glucose-
lowering medication in our pregnant population, it may influence lifestyle behavior and/or glucose 
values in the postpartum period and  thus increase the risk of later prediabetes or diabetes. 
Similarly, further research should investigate, if the diagnosis of prediabetes and/or diabetes would 
worsen mental health symptoms in the following months and years and define the trajectory for 
such a change in order to intervene early. Further studies should also aim at investigating the 
relationship between use of medication and other mental health symptoms, such as anxiety in the 
GDM population. 
 
Acknowledgements 
We would like to give a special thanks to our colleagues that collected and entered data for 
this study: Isabelle Cohen, Justine Gross, Céline Helbling, Stefano Lanzi, Giada Ostinelli and 
Dominique Stulz. 
This study is a pilot project of a study supported by the Swiss National Science Foundation 
(SNF 32003B_176119) and received an unrestricted educational grant from NovoNordisk. The 
Jo
ur
na
l P
re
-p
ro
of
17 
 
funding organizations had no role in the study design, the collection, analysis or interpretation of 
data, nor in the writing of the report or the decision to submit for publication. 
 
Declaration of interest 
The authors declare that they have no known competing financial interests or personal 
relationships that could have appeared to influence the work reported in this paper. 
 
 
Bibliography 
Alexandre, Ketia, Olivier Desrichard, Bernard Burnand, and Isabelle Peytremann-Bridevaux. 2017. 
'Factors influencing self-management in adults with diabetes: an umbrella review protocol', 
JBI database of systematic reviews and implementation reports, 15: 2630-37. 
American Diabetes, Association. 2019. '14. Management of Diabetes in Pregnancy: Standards of 
Medical Care in Diabetes-2019', DIABETES CARE, 42: S165-S72. 
American Diabetes Association. 2020. '14. Management of Diabetes in Pregnancy: Standards of 
Medical Care in Diabetes—2020', DIABETES CARE, 43: S183-S92. 
Arditi C, Burnand B, Puder J. 2017. "Recommendations pour la pratique clinique 2017." In. 
Barger, Steven D, Nadine Messerli-Bürgy, and Jürgen Barth. 2014. 'Social relationship correlates of 
major depressive disorder and depressive symptoms in Switzerland: nationally 
representative cross sectional study', BMC public health, 14: 273. 
Bennett, Heather A, Adrienne Einarson, Anna Taddio, Gideon Koren, and Thomas R Einarson. 2004. 
'Prevalence of depression during pregnancy: systematic review', Obstetrics & Gynecology, 
103: 698-709. 
Blumer, Ian, Eran Hadar, David R Hadden, Lois Jovanovič, Jorge H Mestman, M Hassan Murad, and 
Yariv Yogev. 2013. 'Diabetes and pregnancy: an endocrine society clinical practice guideline', 
The Journal of Clinical Endocrinology & Metabolism, 98: 4227-49. 
Bunevicius, Adomas, Laima Kusminskas, Victor J Pop, Cort A Pedersen, and Robertas Bunevicius. 
2009. 'Screening for antenatal depression with the Edinburgh Depression Scale', Journal of 
Psychosomatic Obstetrics & Gynecology, 30: 238-43. 
Carroll, Dana G, and Kristi W Kelley. 2014. 'Review of metformin and glyburide in the management of 
gestational diabetes', Pharmacy practice, 12. 
Carter, Jasmine, and Walter Swardfager. 2016. 'Mood and metabolism: anhedonia as a clinical target 
in type 2 diabetes', Psychoneuroendocrinology, 69: 123-32. 
Cato, Karin, Sara M Sylvén, Marios K Georgakis, Natasa Kollia, Christine Rubertsson, and Alkistis 
Skalkidou. 2019. 'Antenatal depressive symptoms and early initiation of breastfeeding in 
association with exclusive breastfeeding six weeks postpartum: a longitudinal population-
based study', BMC pregnancy and childbirth, 19: 49. 
Cefalu, William T, Erika Gebel Berg, Mindy Saraco, Matthew P Petersen, Sacha Uelmen, and Shamera 
Robinson. 2019. 'Management of Diabetes in Pregnancy: Standards of Medical Care in 
Diabetes-2019', DIABETES CARE, 42: S165-S72. 
Cesta, Carolyn E, Jacqueline M Cohen, Laura Pazzagli, Brian T Bateman, Gabriella Bröms, Kristjana 
Einarsdóttir, Kari Furu, Alys Havard, Anna Heino, and Sonia Hernandez-Diaz. 2019. 
Jo
ur
na
l P
re
-
ro
of
18 
 
'Antidiabetic medication use during pregnancy: an international utilization study', BMJ Open 
Diabetes Research and Care, 7. 
Christenson, Anne, Eva Johansson, Signy Reynisdottir, Jarl Torgerson, and Erik Hemmingsson. 2016. 
'Women's Perceived Reasons for Their Excessive Postpartum Weight Retention: A 
Qualitative Interview Study', PloS one, 11: e0167731. 
Colberg, Sheri R, Kristin Castorino, and Lois Jovanovič. 2013. 'Prescribing physical activity to prevent 
and manage gestational diabetes', World journal of diabetes, 4: 256. 
Cooper, Peter J, and Lynne Murray. 1998. 'Postnatal depression', Bmj, 316: 1884-86. 
Cox, J. L., J. M. Holden, and R. Sagovsky. 1987. 'Detection of postnatal depression. Development of 
the 10-item Edinburgh Postnatal Depression Scale', The British journal of psychiatry, 150: 
782-86. 
Crowther, Caroline A, Janet E Hiller, John R Moss, Andrew J McPhee, William S Jeffries, and Jeffrey S 
Robinson. 2005. 'Effect of treatment of gestational diabetes mellitus on pregnancy 
outcomes', New England Journal of Medicine, 352: 2477-86. 
Damé, Patrícia, Kadhija Cherubini, Pâmella Goveia, Geórgia Pena, Leony Galliano, Cristina Façanha, 
and Maria Angélica Nunes. 2017. 'Depressive Symptoms in Women with Gestational 
Diabetes Mellitus: The LINDA-Brazil Study', Journal of diabetes research, 2017. 
Daniells, Suzie, Brin FS Grenyer, Warren S Davis, Keith J Coleman, Julie-Anne P Burgess, and Robert G 
Moses. 2003. 'Gestational diabetes mellitus: is a diagnosis associated with an increase in 
maternal anxiety and stress in the short and intermediate term?', DIABETES CARE, 26: 385-
89. 
Fowles, Eileen R, Christina Murphey, and Roberta Jeanne Ruiz. 2011. 'Exploring relationships among 
psychosocial status, dietary quality, and measures of placental development during the first 
trimester in low-income women', Biological research for nursing, 13: 70-79. 
Gilbert, L., J. Gross, S. Lanzi, D. Y. Quansah, J. Puder, and A. Horsch. 2019. 'How diet, physical activity 
and psychosocial well-being interact in women with gestational diabetes mellitus: an 
integrative review', BMC Pregnancy Childbirth, 19: 60. 
Grace, Sherry L, Alexandra Evindar, and DE Stewart. 2003. 'The effect of postpartum depression on 
child cognitive development and behavior: a review and critical analysis of the literature', 
Archives of women’s mental health, 6: 263-74. 
Guedeney, N, and J Fermanian. 1998. 'Validation study of the French version of the Edinburgh 
Postnatal Depression Scale (EPDS): new results about use and psychometric properties', 
European psychiatry, 13: 83-89. 
Hajos, Tibor RS, F Pouwer, SE Skovlund, Brenda L Den Oudsten, PHLM Geelhoed‐Duijvestijn, CJ Tack, 
and Frank J Snoek. 2013. 'Psychometric and screening properties of the WHO‐5 well‐being 
index in adult outpatients with Type 1 or Type 2 diabetes mellitus', Diabetic Medicine, 30: 
e63-e69. 
Henkel, Verena, Roland Mergl, Ralf Kohnen, Wolfgang Maier, Hans-Jürgen Möller, and Ulrich Hegerl. 
2003. 'Identifying depression in primary care: a comparison of different methods in a 
prospective cohort study', Bmj, 326: 200-01. 
Herring, Sharon J, Janet W Rich‐Edwards, Emily Oken, Sheryl L Rifas‐Shiman, Ken P Kleinman, and 
Matthew W Gillman. 2008. 'Association of postpartum depression with weight retention 1 
year after childbirth', Obesity, 16: 1296-301. 
Hinkle, Stefanie N., Germaine M. Buck Louis, Shristi Rawal, Yeyi Zhu, Paul S. Albert, and Cuilin Zhang. 
2016. 'A longitudinal study of depression and gestational diabetes in pregnancy and the 
postpartum period', Diabetologia, 59: 2594-602. 
Hochberg, G, S Pucheu, L Kleinebreil, S Halimi, and C Fructuoso-Voisin. 2012. 'WHO-5, a tool focusing 
on psychological needs in patients with diabetes: The French contribution to the DAWN 
study', Diabetes & metabolism, 38: 515-22. 
Horsch, Antje, Ji Seon Kang, Yvan Vial, Ulrike Ehlert, Ayala Borghini, Pedro Marques-Vidal, Ingo 
Jacobs, and Jardena J. Puder. 2016. 'Stress exposure and psychological stress responses are 
Jo
ur
n
l P
re
-p
ro
of
19 
 
related to glucose concentrations during pregnancy', British journal of health psychology: 
n/a-n/a. 
Lehmann, Roger, Troendle, and Brändle. 2009. 'Neue Erkenntnisse zur Diagnostik und Management 
des Gestationsdiabetes', Therapeutische Umschau, 66: 695-706. 
Mak, Jonathan KL, Andy H Lee, Ngoc Minh Pham, Li Tang, Xiong-Fei Pan, Colin W Binns, and Xin Sun. 
2019. 'Gestational diabetes and postnatal depressive symptoms: A prospective cohort study 
in Western China', Women and Birth, 32: e427-e31. 
Metzger, Boyd E, Thomas A Buchanan, Donald R Coustan, Alberto De Leiva, David B Dunger, David R 
Hadden, Moshe Hod, John L Kitzmiller, Siri L Kjos, and Jeremy N Oats. 2007. 'Summary and 
recommendations of the fifth international workshop-conference on gestational diabetes 
mellitus', DIABETES CARE, 30: S251-S60. 
Metzger, Boyd E., Steven G. Gabbe, Bengt Persson, Thomas A. Buchanan, Patrick A. Catalano, Peter 
Damm, Alan R. Dyer, Alberto de Leiva, Moshe Hod, John L. Kitzmiler, Lynn P. Lowe, H. David 
McIntyre, Jeremy J. N. Oats, Yasue Omori, and Maria Ines Schmidt. 2010. 'International 
association of diabetes and pregnancy study groups recommendations on the diagnosis and 
classification of hyperglycemia in pregnancy', DIABETES CARE, 33: 676-82. 
Molyneaux, Emma, Shahina Begum, Annette L Briley, Paul T Seed, Louise M Howard, and Lucilla 
Poston. 2018. 'Do elevated symptoms of depression predict adherence and outcomes in the 
UPBEAT randomised controlled trial of a lifestyle intervention for obese pregnant women?', 
BMC pregnancy and childbirth, 18: 378. 
Mortazavi, Forough, S-A Mousavi, Reza Chaman, and Ahmad Khosravi. 2015. 'Validation of the World 
Health Organization-5 Well-Being Index; assessment of maternal well-being and its 
associated factors', Turk Psikiyatri Dergisi, 26: 1-7. 
Nicklas, Jacinda M, Laura J Miller, Chloe A Zera, Roger B Davis, Sue E Levkoff, and Ellen W Seely. 
2013. 'Factors associated with depressive symptoms in the early postpartum period among 
women with recent gestational diabetes mellitus', Maternal and child health journal, 17: 
1665-72. 
Panel, Clinical Chemistry and Clinical Toxicology Devices. 2016. 'FDA Public Advisory Meeting Alere 
Afinion™ HbA1c Dx'. https://www.fda.gov/media/99241/download. 
Robertson, S. M., M. A. Stanley, J. A. Cully, and A. D. Naik. 2012. 'Positive emotional health and 
diabetes care: concepts, measurement, and clinical implications', Psychosomatics, 53: 1-12. 
Rowan, J. A., W. M. Hague, W. Gao, M. R. Battin, M. P. Moore, and G. Trial Investigators Mi. 2008. 
'Metformin versus insulin for the treatment of gestational diabetes', N Engl J Med, 358: 
2003-15. 
Ruchat, Stephanie‐May, and Michelle F Mottola. 2013. 'The important role of physical activity in the 
prevention and management of gestational diabetes mellitus', Diabetes/metabolism 
research and reviews, 29: 334-46. 
Ruohomäki, Aleksi, Elena Toffol, Subina Upadhyaya, Leea Keski-Nisula, Juha Pekkanen, Jussi Lampi, 
Sari Voutilainen, Tomi-Pekka Tuomainen, Seppo Heinonen, and Kirsti Kumpulainen. 2018. 
'The association between gestational diabetes mellitus and postpartum depressive 
symptomatology: A prospective cohort study', Journal of affective disorders, 241: 263-68. 
Topp, C. W., S. D. Østergaard, S. Søndergaard, and P. Bech. 2015. 'The WHO-5 Well-Being Index: A 
Systematic Review of the Literature', Psychotherapy and psychosomatics, 84: 167-76. 
Varela, Pinelopi, Areti C Spyropoulou, Zacharias Kalogerakis, Eleni Vousoura, Martha Moraitou, and 
Iannis M Zervas. 2017. 'Association between gestational diabetes and perinatal depressive 
symptoms: evidence from a Greek cohort study', Primary health care research & 
development, 18: 441-47. 
Webber, Jonathan, Mary Charlton, and Nina Johns. 2015. 'Diabetes in pregnancy: management of 
diabetes and its complications from preconception to the postnatal period (NG3)', British 
Journal of Diabetes, 15: 107-11. 
Jo
ur
n
l P
re
-p
ro
of
20 
 
Wersebe, Hanna, Roselind Lieb, Andrea H Meyer, Marcel Miche, Thorsten Mikoteit, Christian 
Imboden, Jürgen Hoyer, Klaus Bader, Martin Hatzinger, and Andrew T Gloster. 2018. 'Well-
being in major depression and social phobia with and without comorbidity', International 
Journal of Clinical and Health Psychology. 
Wilson, C, J Newham, J Rankin, K Ismail, Emily Simonoff, RM Reynolds, N Stoll, and LM Howard. 
2019. 'Is there an increased risk of perinatal mental disorder in women with gestational 
diabetes? A systematic review and meta‐analysis', Diabetic Medicine. 
Wood, Jamie R, Brett M Kaminski, Craig Kollman, Roy W Beck, Callyn A Hall, Jason P Yun, Eda Cengiz, 
Michael J Haller, Krishna Hassan, and Georgeanna J Klingensmith. 2012. 'Accuracy and 
precision of the Axis-Shield Afinion hemoglobin A1c measurement device', Journal of 
diabetes science and technology, 6: 380-86. 
 
 
Figures and Tables 
 
 
Figure 1. Flow chart describing how the study participants were selected. 
* First and last GDM clinical visit were the predefined essential time points providing indispensable 
information regarding the two main aims: baseline mental health and valid information regarding 
glucose-lowering medication. Systematic distribution of mental health questionnaires started on 
01.01.2016 and women that were followed before this time point were also excluded. 
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Figure 2:  
Overall effect of time showing significant decreases in mean depression (FIG 2a; Edinburgh Postnatal 
Depression Scale (EPDS)) and well-being (FIG 2b; World Health Organization Well-being Index; (WHO-
5)) scores in the overall sample (B=-1.74, CI= -2.22 – -1.26, p<0.01 and B=2.49, CI= 1.34 – 3.64, 
p<0.01). For illustrative purposes, women with and without glucose-lowering medication are 
separated. Of all interaction effects tested, the only significant finding relates to the presence or not 
of clinically relevant depression at the first GDM visit on the association between glucose-lowering 
medication in pregnancy and well-being at the postpartum visit (p for interaction = 0.01 and shown 
as a star on figure 2b). Values are shown as means and standard errors. 
  
Jo
ur
na
l P
r
-p
ro
of
22 
 
 
 
 
Table 1. Descriptive maternal sociodemographic and medical parameters  
 All With glucose-
lowering 
medication 
Without glucose-
lowering 
medication 
 Mean (SD) or n 
(%)  
Mean (SD) or n (%) Mean (SD) or n 
(%) 
Maternal sociodemographic variables 
Age (years) 33.62 (5.34) 33.39 (5.27) 33.84 (5.41) 
Educational level    
   No education 3 (0.9%) 1 (0.6%) 2 (1.1%) 
   Compulsory education not 
completed 
17 (5%) 8 (4.9%) 9 (5.1%) 
   Compulsory education completed 60 (17.6%) 33 (20.3%) 27 (15.2%) 
   Secondary school 38 (11.1%) 18 (11%) 20 (11.2%) 
   Apprenticeship 55 (16.1%) 29 (17.8%) 26 (14.6%) 
   University degree 113 (33.1%) 46 (28.2%) 67 (37.6%) 
Social support    
   Lives: alone without support, alone 
with support, with partner 
13 (3.8%), 14 
(4.1%), 292 
(85.6%) 
9 (5.5%), 2 (1.2%), 
138 (84.7%) 
4 (2.2%), 12 
(6.7%), 154 
(86.5)* 
Obstetric variables    
Gestational age at first GDM clinical 
visit 
28.85 (3.38) 28.13 (3.85) 29.51 (2.74) * 
Gestational age at last GDM clinical 
visit 
36.44 (1.28) 36.34 (1.31) 36.53 (1.25) 
GDM variables    
HbA1c at first GDM clinical visit  % - 
(mmol/mol) 
5.4 (0.43) – 
(35 (4.32)) 
5.5 (0.51) – (37 
(5.09)) 
5.3 (0.31) (34 
(3.11))* 
Family history of diabetes: None, First 
and Second degree relative 
126 (37%), 122 
(35.8%), 71 
(20.8%) 
56 (34.4%), 63 
(38.7%), 33 (20.2%) 
70 (39.2%), 59 
(33.1%), 38 
(21.3%) 
Mental health variables    
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Depression score at first GDM clinical 
visit 
7.43 (5.46) 7.49 (5.75) 7.38 (5.20) 
Women with clinically relevant 
symptoms (cut-off ≥ 11) at first GDM 
clinical visit 
77 (25.2%) 42 (28.8%) 35 (22%) 
Detailed glucose-lowering medication for the overall sample 
 n (%)  
No glucose-lowering medication intake (1) 178 (52.2%)  
Metformin only (2) 15 (4.4%)  
Long-acting (basal) bedtime insulin (±metformin) (3) 64 (18.8%)  
Short-acting (meal) insulin (± long-acting bedtime 
insulin and/or metformin) (4) 
84 (24.6%)  
Continuous and normally distributed variables were described as means and standard deviations and 
ordinal outcomes were described as frequencies and percentages. *Indicates a significant difference 
(p<0.05) between the subgroups with and without glucose-lowering medication, respectively. 
BMI: body mass index. 
 
 
 
 
Table 2. Prospective associations between detailed glucose-lowering medication during pregnancy 
and subsequent mental health. 
 
 Model 1 Model 2 
 Well-being scores at the last GDM clinical visit 
Metformin vs none B= -0.62 (CI= -11.66 – 10.43) B= -0.99 (CI= -11.63 – 9.65) 
Long-acting Insulin vs none B= -2.95 (CI= -8.86 – 2.96) B= -1.99 (CI= -7.79 – 3.82) 
Short-acting Insulin vs none B= -0.54 (CI= -6.22 – 5.13) B= -0.24 (CI= -5.84 – 5.36) 
 Well-being scores at the postpartum clinical visit 
Metformin vs none B= 11.65 (CI= 1.06 – 22.24)* B= 11.42 (CI= 0.92 – 21.92)* 
Long-acting Insulin vs none B= -1.97 (CI= -7.60 – 3.67) B= -1.41 (CI= -7.16 – 4.34) 
Short-acting Insulin vs none B= 1.26 (CI= -4.04 – 6.55) B= 1.57 (CI= -3.81 – 6.95) 
 Depression scores at the postpartum clinical visit 
Metformin vs none B= -0.15 (CI= -2.64 – 2.34) - 
Long-acting Insulin vs none B= 1.00 (CI= -0.34 – 2.31) - 
Short-acting Insulin vs none B= 0.46 (CI= -1.72 – 0.80) - 
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Results reported as β-Coefficient (95% confidence interval) from a general linear model.  
The following three categories are compared to “no glucose-lowering medication” (termed “none”) 
being used as a reference category (1): metformin only (2), long-acting (basal) bedtime insulin 
(±metformin) (3), and short-acting (meal) insulin (± long-acting bedtime insulin and/or metformin) 
(4). 
Model 1 adjusted for maternal age and gestational age at first GDM clinical visit. 
Model 2 adjusted for maternal age, gestational age, family history of diabetes and well-being at the 
first GDM clinical visit, except for the analyses with depression scores at the postpartum clinical visit 
for which no additional confounders were added, as no additional confounders were significantly 
correlated to the dependent variable. 
* p <0.05 
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Highlights  
 Gestational diabetes (GDM) is usually associated with poorer mental health.  
 In our sample, mental health improves after GDM diagnosis; during and after pregnancy.  
 Poorer mental health does not increase the need for medical therapy in GDM. 
 Medical therapy does not impact on mental health during and after pregnancy. 
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